Assembly Biosciences Announces Positive Phase 1b Results

Assembly Biosciences ( (ASMB) ) has provided an announcement.

On August 8, 2025, Assembly Biosciences announced positive interim results from its Phase 1b clinical study of ABI-5366, a long-acting herpes simplex virus helicase-primase inhibitor candidate for recurrent genital herpes. The study showed a 94% reduction in HSV-2 shedding rate and genital lesion rate, and a 98% reduction in high viral load shedding rate compared to placebo, with the 350 mg weekly dose. The results exceeded the company’s targets and demonstrated a favorable safety profile, supporting the potential for once-weekly and once-monthly dosing regimens. These findings pave the way for Phase 2 clinical study preparations, with the company expecting to initiate these studies in mid-2026.

The most recent analyst rating on (ASMB) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.

Spark’s Take on ASMB Stock

According to Spark, TipRanks’ AI Analyst, ASMB is a Neutral.

The overall score reflects significant financial challenges, with the company’s lack of revenue and negative cash flows weighing heavily. However, positive technical momentum and a recent successful clinical trial offer potential upside. Valuation metrics remain weak due to negative earnings, highlighting risk for investors.

To see Spark’s full report on ASMB stock, click here.

More about Assembly Biosciences

Assembly Biosciences, Inc. is a biotechnology company focused on developing innovative therapeutics targeting serious viral diseases.

Average Trading Volume: 31,792

Technical Sentiment Signal: Hold

Current Market Cap: $148.4M

Learn more about ASMB stock on TipRanks’ Stock Analysis page.